A team from CEITEC Masaryk University (MUNI) in collaboration with researchers from two research institutes in Norway has, for the first time, captured how echovirus 18, a member of the enterovirus genus, releases its genetic material into cells to initiate infection. The study provides a structural view of an early stage of viral infection under near-native conditions. Using cryo-electron microscopy, the researchers discovered that the virus does not release its RNA through a small pore in its capsid, as had long been assumed. Instead, its protein shell partially disassembles, creating a large opening through which the viral genetic material escapes into the host cell. A detailed understanding of this genome release mechanism could eventually help develop compounds preventing enteroviruses from infecting cells.Enteroviruses are common human pathogens causing diseases ranging from the common cold and gastrointestinal infections to severe neurological disorders. Echovirus 18, the virus investigated in this study, is known primarily as a cause of meningitis and encephalitis in children. It belongs to the picornaviruses, a family of small, non-enveloped viruses whose genetic material is protected by a protein shell, the capsid, organized with icosahedral symmetry.To replicate within a cell, the enteroviruses must release their RNA – the molecule that carries viral genetic information – from the capsid, into the cell cytoplasm. Although this step is crucial for initiating infection, it has never been observed in infected cells.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Vedci_z_CEITEC_jako_prvni_zachytili_jak_enteroviry_spousteji_infekci_bunek_71d553bb0e.jpg" alt="CEITEC/Plevka Lab: CEITEC Scientists Are the First to Capture How Enteroviruses Initiate Infection: View into a cell infected by echovirus 18. Echovirus 18 is shown in green and yellow, ribosomes in violet, and actin filaments in cyan. Scale 50 nm. " srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Vedci_z_CEITEC_jako_prvni_zachytili_jak_enteroviry_spousteji_infekci_bunek_71d553bb0e.jpg 221w," sizes="100vw" width="1600" height="1128">“For a long time, two main theories existed about how picornaviruses deliver their RNA genomes into cells. One proposed that the genome leaves the capsid through a small opening. The other, supported by earlier work from our laboratory, suggested that the genome escapes from partially disassembled capsids missing pentamers of capsid proteins. However, both models were based on experiments with virus particles outside cells. We wanted to go one step further and see what really happens during infection inside a cell,” says <a target="_blank" rel="noopener noreferrer" href="https://www.ceitec.eu/liya-mukhamedova-ph-d/u89248?page=publication">Liya Mukhamedova</a>, the study’s first author from CEITEC MUNI.Using cryo-electron microscopy, which allows scientists to visualize biological structures at exceptionally high resolution, the researchers observed individual echovirus 18 particles directly within infected cells. They discovered that empty virus particles in infected cells lack parts of their capsids. It is through these openings that the virus releases its RNA.The study also revealed the role of the FcRn receptor, a cell-surface molecule that enteroviruses use to enter cells. The binding of the virus to the receptor triggers structural changes in the viral particle that prime it for subsequent genome release. The team showed that receptor binding causes the loss of the so-called pocket factor, a small molecule that normally helps stabilize the virus particle. The virus otherwise remains largely intact, suggesting that receptor binding is only the first step toward uncoating, while additional factors within the cell are required to complete the process and trigger genome release.“Infection is a complex process, during which enterovirus particles sense various interactions with cell components. The binding of echovirus 18 to the FcRn host-cell receptor triggers conformational changes in the virus, priming it for genome release.” – explains <a target="_blank" rel="noopener noreferrer" href="https://www.ceitec.eu/pavel-plevka-ph-d/u26854">Pavel Plevka</a>, head of the Structural Virology Research Group.The researchers did not observe the so-called activated particles that are key intermediates in the enterovirus uncoating process. This suggests that genome release in cells occurs much faster than previous experiments had suggested.By combining structural data obtained from studies of virus particles outside living cells with observations of infected cells, the study offers a picture of how enterovirus infection begins. Moving beyond simplified experiments with isolated virus particles, it brings scientists closer to understanding the earliest stages of enterovirus infection as they occur in living cells. The study, was published in the <a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1073/pnas.2601182123">PNAS journal</a>.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Vedci_z_CEITEC_jako_prvni_zachytili_jak_enteroviry_spousteji_infekci_bunek_2_3601bf1df9.jpg" alt="CEITEC/Plevka Lab: CEITEC Scientists Are the First to Capture How Enteroviruses Initiate Infection: Reconstructions of E18 particles from infected cells. The particles are rainbow-colored based on the distance from the particle center. Scale 10 nm." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Vedci_z_CEITEC_jako_prvni_zachytili_jak_enteroviry_spousteji_infekci_bunek_2_3601bf1df9.jpg 245w," sizes="100vw" width="1600" height="906"><blockquote><h4>Article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://www.pnas.org/doi/10.1073/pnas.2601182123">Particles of echovirus 18 open to release their genomes in vivo</a></h4>Liya Mukhamedova, David Buchta, Zuzana Trebichalská, Yevgen Levdansky, Jana Moravcová, David Potěšil, Zbyněk Zdráhal, Dominik Hřebík, Lucie Nepovímová, Torleif Tollefsrud Gjølberg, Jan Terje Andersen, Jiří Nováček, Tibor Füzik, and Pavel PlevkaProc. Natl. Acad. Sci. U.S.A., 2026, 123, e2601182123<div>&nbsp;</div><div><a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1073/pnas.2601182123">https://doi.org/10.1073/pnas.2601182123</a></div><h6>licenced under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote><h4>Abstract</h4>Enteroviruses cause a broad spectrum of human diseases, ranging from mild respiratory or gastrointestinal infections to severe neurological disorders such as aseptic meningitis and encephalitis. Enterovirus cell entry involves receptor-mediated endocytosis followed by destabilizing rearrangements of the virus capsid that enable genome release. However, the mechanism of enterovirus genome release has not been visualized in infected cells. Here, we used cryoelectron tomography and microscopy to image echovirus 18 (E18) entry into host cells and its interaction with the neonatal Fc receptor (FcRn). 30 min postinfection, endosomes and cytoplasm contained empty capsids missing one or several pentamers of capsid proteins, providing evidence that in vivo E18 releases its genome through capsid opening. In vitro, FcRn binding induced the expulsion of pocket factors from hydrophobic pockets in VP1, priming the virus for uncoating. The cryoelectron microscopy reconstruction of genome-containing particles of E18 inside infected cells did not reveal pocket factors, indicating that receptor binding triggers the same priming process during infection. We did not detect activated particles in infected cells, suggesting that these intermediates are short-lived and rapidly release their genomes in vivo. Our results identify capsid opening as the in vivo mechanism of echovirus 18 genome release, providing structural evidence for a process previously only inferred from in vitro experiments.

CEITEC Scientists Are the First to Capture How Enteroviruses Initiate Infection 

Gas chromatography (GC) is a powerful analytical technique used to separate and analyze compounds in a mixture. Whether you're working in pharmaceuticals, environmental testing, or food safety, understanding the key components of a gas chromatograph is essential for accurate and efficient results.In this article, we will delve into the primary components of gas chromatography, including the injector, column, detector, and carrier gas—and explain how each plays a critical role in the separation and analysis process.By mastering these elements, you can optimize your GC setup for precise and reliable outcomes. Let's explore each component in detail:<h3>Sample Injector</h3>The injector is the starting point in the <a target="_blank" rel="noopener noreferrer" href="https://www.phenomenex.com/techniques/gc">gas chromatography process</a>, where the sample is introduced into the system. In GC, the sample must be vaporized into a gas before it enters the column. The injector serves this purpose by heating the sample to its gaseous state. There are many types of injectors, Split/Splitless, PTV, on column.The most common injector is the Split/Splitless injector that can be used in split mode or in splitless mode:<ul><li>Split Injection: This mode allows a portion of the sample to be sent to the column while the remainder is vented. It is useful for high-concentration samples to prevent system overload.</li><li>Splitless Injection: In this mode, the entire sample is introduced into the column, making it ideal for trace analysis where even minute quantities need detection.</li></ul>Proper choice of injector type and proper control of injection conditions, such as temperature, sample size, injection mode are crucial for achieving reproducible and reliable results.<h3>Carrier Gas</h3>In gas chromatography, the mobile phase is represented by carrier gas, which transports the vaporized sample through the column. The carrier gas is an inert gas, such as helium, nitrogen, or hydrogen. The choice of carrier gas can influence the efficiency of the separation process.<ul><li>Helium is the most used carrier gas due to its inertness and high flow rate.</li><li>Hydrogen offers faster analysis times but requires careful handling due to its flammability.</li><li>Nitrogen provides a cheaper solution compared to Helium, although it's slower than helium or hydrogen.</li></ul>The flow rate and pressure of the carrier gas need to be carefully controlled to ensure that the sample moves smoothly through the system and adequate efficiency is generated.<h3>Column/Stationary Phase</h3>The column is the heart of the gas chromatograph, where the actual separation of compounds occurs. <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/gcms/products?category=7&amp;manufacturerItems=50">GC columns</a> are typically long, thin tubes made from stainless steel or fused silica. They are coated with a stationary phase, which interacts with the components of the sample as they pass through.<ul><li>Packed Columns: These contain small particles of stationary phase material and generally have a larger volume. While they are less efficient than capillary columns, they can be suitable for specific applications.</li><li>Capillary Columns: These thin tubes are coated with a stationary phase, offering higher resolution and faster analysis times due to their smaller diameter.</li></ul>The length, diameter, and type of stationary phase of the column are important factors that affect the efficiency and selectivity of the separation. The choice of stationary phase (polar or non-polar; liquid-coated or solid) affects how different compounds interact with it.As the sample moves through the column, compounds separate based on volatility and their affinity for the stationary phase, resulting in distinct peaks in the chromatogram.<h3>Detector</h3>Once the sample has passed through the column, it reaches the detector, where individual components are identified and measured. There are several types of detectors, each suited to different applications:<ul><li>Flame Ionization Detector (FID): One of the most commonly used detectors in GC. It measures ions produced when organic compounds are burned in a hydrogen-air flame. FID is highly sensitive to a wide range of organic compounds and offers a broad linear dynamic range.</li><li>Thermal Conductivity Detector (TCD): Detects changes in the thermal conductivity of the gas stream as analytes elute from the column. It is a universal, non-destructive detector, but is generally less sensitive than FID.</li><li>Electron capture detector (ECD): A very sensitive and selective detector used to detect chlorinated compounds it is easily contaminated and requires very pure and dry carrier and makeup gases and difficult maintenance.</li><li>Mass Spectrometer (MS): Provides structural information, aiding in both identification and quantification. Requires advanced and trained users and it’s difficult to maintain.</li></ul>The choice of detector depends on the type of analysis being performed and the sensitivity required. Each detector converts physical or chemical changes associated with the analytes into a measurable signal, producing a chromatogram that reflects concentration and retention time.<h3>Data System</h3>Although not a physical part of the chromatograph, the data system plays an integral role in processing and interpreting the signals generated by the detector. Modern gas chromatographs are equipped with software that converts detector signals into chromatograms—visual representations of the separation process. The software allows users to quantify and identify the components of the sample based on retention times and peak areas.<h3>How to Read a Gas Chromatogram?</h3>Interpreting a gas chromatogram involves understanding its essential elements, such as peaks, retention times, and the overall data for qualitative and quantitative analysis.<h4>The Nature of the Sample</h4>Begin by considering the sample's characteristics; different samples, such as environmental pollutants or food components, may exhibit distinct peak patterns. Recognizing the baseline (the flat line representing the signal without analytes) is crucial for identifying peaks accurately. While well-defined peaks indicate successful separation of components, poorly shaped or broad peaks may suggest issues with the separation process. For instance, if a mixture is injected and three peaks are observed, it indicates the presence of three different compounds in the sample. Conversely, when evaluating the purity of a sample, one would anticipate observing a single peak. Ideally, the chromatogram should reflect this expectation, confirming the sample's purity.<h4>The Identity of the Sample</h4>Retention time (Rt) is a critical factor in identifying the compounds present in the sample. Each analyte has a characteristic retention time that can be compared to known standards or literature. To confirm identities, a standard mixture should run alongside the sample; this allows to correlate retention times with specific compounds. If available, utilizing MS in conjunction with gas chromatography (GC-MS) can provide additional structural information, enhancing identification accuracy. With HR-MS or MS-MS detectors, unknown compounds can be identified by matching perfectly the Molecular weight or by matching the fragmentation pattern.<h4>The Amount of Sample</h4>Quantifying analytes involves analyzing peak area or height, which is directly proportional to the concentration of the analyte in the sample. A calibration curve constructed from known concentrations can help relate peak areas to actual concentrations. It is essential to consider the detector’s sensitivity and the limits of detection, as peaks below a certain threshold may not provide reliable quantification.

Basic Principles of Gas Chromatography - Separation and Analysis

ISC 2026 - Day 2

Article

Events

Academy

Science and research

Since its establishment in 2011, CEITEC has quickly developed into a cutting-edge infrastructure for research which performs highly alongside the best institutes in Europe. Among the main priorities of CEITEC are the promotion of a motivating and dynamic international scientific environment, the provision of state-of-the-art research infrastructure, and the policy of open communication and equal opportunities.

CEITEC

Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, government and academic laboratories.

Phenomenex

The International Symposium on Chromatography (ISC) represents the oldest conference series focussing on separation science. ISC symposia have been organised since 1956 in each even year. ISC is internationally recognised as one of the premier meeting series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.

International Symposium on Chromatography - (ISC)

SR-9011 analysis

Targeted HPLC analysis of SR-9011 in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The SR-9011 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of SR-9011 in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About SR-9011</h4>SR-9011 is a synthetic research compound commonly described as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are involved in the regulation of circadian rhythms, metabolism, sleep, and other physiological processes.SR-9011 has been investigated mainly in preclinical and laboratory studies examining circadian regulation, cellular metabolism, inflammatory processes, and cancer-cell viability. It has not been approved for therapeutic use.<h4>Key Features</h4><ul><li>Targeted identification and quantification of SR-9011</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: SR-9011</li><li>CAS number: 1379686-29-9</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for SR-9011. It does not automatically screen the sample for SR-9009, other REV-ERB agonists, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of SR-9011 required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Cagrilintide analysis

HPLC analysis of cagrilintide for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of cagrilintide in lyophilized samples and raw API powders. HPLC testing provides information about the actual content of the target peptide and its purity relative to chromatographically detectable impurities.<h4>Cagrilintide</h4>Cagrilintide is a synthetic, lipidated, long-acting amylin analogue. Its molecular structure was developed to improve stability and extend its duration of action compared with native amylin. Scientific and clinical literature describes cagrilintide as an investigational peptide rather than a generally available approved active substance.Its structure contains modified amino acid residues and an amidated C-terminus. The stated molecular weight is approximately 4,409 Da.HPLC analysis confirms the presence of cagrilintide in the sample, determines its amount and evaluates peptide purity.<h4>What the Analysis Determines</h4><ul><li>Identity of cagrilintide</li><li>Amount of cagrilintide in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: cagrilintide</li><li>CAS number: 1415456-99-3</li><li>Molecular weight: 4,409 Da</li><li>Sequence: Unk-Glu-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Vas-Gly-Ser-Asn-Thr-Pro-NH2</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of cagrilintide in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).<h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Clomiphene analysis

Targeted HPLC analysis of clomiphene in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Clomiphene Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of clomiphene in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Clomiphene&nbsp;</h4>Clomiphene, also known by the trade name Clomid, is an orally active, non-steroidal selective estrogen receptor modulator (SERM). It interacts with estrogen receptors and can exert estrogenic or anti-estrogenic effects depending on the target tissue. Clomiphene is used clinically to induce ovulation in selected patients with ovulatory dysfunction.The compound is commonly administered as clomiphene citrate and consists of two geometric isomers, enclomiphene and zuclomiphene, which differ in their biological properties.<h4>Key Features</h4><ul><li>Targeted identification and quantification of clomiphene</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Clomiphene</li><li>Other name: Clomid</li><li>CAS number: 911-45-5</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 5 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for clomiphene. It does not automatically screen the sample for enclomiphene, zuclomiphene, other selective estrogen receptor modulators, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of clomiphene required for evaluation is 5 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Cagrilintide/Semaglutide (CagriSema) blend analysis

HPLC analysis of a CagriSema blend for identification and separate quantification of cagrilintide and semaglutide in mg per vial.

This analysis is designed to confirm the identity and separately determine the amount of cagrilintide and semaglutide in a combined lyophilized sample. HPLC testing measures the content of both target peptides, with results reported in mg per vial.Peptide purity cannot be reliably determined in a blend because impurities originating from the individual peptides may overlap in the chromatographic data and cannot be clearly attributed to a specific component.<h4>CagriSema</h4>CagriSema refers to a combination of cagrilintide and semaglutide in a single product. Cagrilintide is a synthetic lipidated amylin analogue, while semaglutide is a modified GLP-1 peptide analogue.Because the sample contains two different peptide components, the analysis focuses on confirming their identity and separately determining the amount of each peptide. The report therefore provides individual results for cagrilintide and semaglutide.<h4>What the Analysis Determines</h4><ul><li>Identity of cagrilintide</li><li>Identity of semaglutide</li><li>Amount of cagrilintide in the sample</li><li>Amount of semaglutide in the sample</li><li>Results in mg per vial for each target peptide</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: cagrilintide and semaglutide</li><li>Blend name: CagriSema</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format: mg per vial for each target peptide</li><li>Minimum sample amount: one whole unopened vial containing the lyophilizate</li><li>Average turnaround time: 7 business days</li><li>Peptide purity: not measured</li></ul><blockquote><h5>Important Notice</h5>Peptide purity cannot be determined for a cagrilintide/semaglutide blend. Impurities associated with both peptides may overlap in the chromatographic data and cannot be reliably assigned to the individual target compounds.The final report provides identification and separately measured amounts of cagrilintide and semaglutide. Peptide purity is not included in the results.</blockquote><h4>Additional Analyses</h4><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Enclomiphene analysis

Targeted HPLC analysis of enclomiphene in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Enclomiphene Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of enclomiphene in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Enclomiphene&nbsp;</h4>Enclomiphene is the trans-isomer of clomiphene and is classified as a non-steroidal selective estrogen receptor modulator (SERM). It interacts with estrogen receptors and can reduce estrogen-mediated negative feedback within the hypothalamic–pituitary–gonadal axis, thereby influencing the secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH).Enclomiphene has been investigated in clinical studies focused primarily on hormonal regulation and testosterone levels in men with secondary hypogonadism.<h4>Key Features</h4><ul><li>Targeted identification and quantification of enclomiphene</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Enclomiphene</li><li>CAS number: 15690-57-0</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 5 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for enclomiphene. It does not automatically screen the sample for clomiphene, zuclomiphene, other selective estrogen receptor modulators, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of enclomiphene required for evaluation is 5 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Raloxifene analysis

Targeted HPLC analysis of raloxifene in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Raloxifene Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of raloxifene in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Raloxifene&nbsp;</h4>Raloxifene, also marketed under names such as Evista and Raloxo, is an orally active, non-steroidal selective estrogen receptor modulator (SERM). It acts as an estrogen agonist in some tissues and as an antagonist in others.Raloxifene is used clinically for the prevention and treatment of osteoporosis in postmenopausal women and for reducing the risk of invasive breast cancer in selected postmenopausal patients.<h4>Key Features</h4><ul><li>Targeted identification and quantification of raloxifene</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Raloxifene</li><li>Other names: Evista, Raloxo</li><li>CAS number: 84449-90-1</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 5 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for raloxifene. It does not automatically screen the sample for other selective estrogen receptor modulators, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of raloxifene required for evaluation is 5 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Tamoxifen analysis

Targeted HPLC analysis of tamoxifen in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Tamoxifen Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of tamoxifen in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Tamoxifen&nbsp;</h4>Tamoxifen, also marketed under names such as Nolvadex and Nolva, is an orally active, non-steroidal selective estrogen receptor modulator (SERM). It binds to estrogen receptors and can act as an estrogen antagonist or agonist depending on the target tissue.Tamoxifen is used clinically in the treatment and risk reduction of hormone receptor-positive breast cancer. It is commonly administered as tamoxifen citrate and is metabolised into active compounds that contribute to its pharmacological effects.<h4>Key Features</h4><ul><li>Targeted identification and quantification of tamoxifen</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Tamoxifen</li><li>Other names: Nolvadex, Nolva</li><li>CAS number: 10540-29-1</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 5 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for tamoxifen. It does not automatically screen the sample for tamoxifen metabolites, other selective estrogen receptor modulators, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of tamoxifen required for evaluation is 5 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Cartalax analysis

HPLC analysis of Cartalax for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of Cartalax in lyophilized samples and raw API powders. HPLC testing provides information about the actual content of the target peptide and its purity relative to chromatographically detectable impurities.<h4>Cartalax</h4>Cartalax, also known as AED, is an ultrashort peptide composed of three amino acids: alanine, glutamic acid and aspartic acid. Its sequence is written as Ala-Glu-Asp. Scientific literature classifies it among short regulatory peptides investigated in relation to cellular and molecular processes.HPLC analysis confirms whether the sample contains Cartalax, determines its amount and evaluates peptide purity.<h4>What the Analysis Determines</h4><ul><li>Identity of Cartalax</li><li>Amount of Cartalax in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Cartalax</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of cartalax in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).<h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

CJC with DAC/Ipamorelin Blend Analysis

HPLC analysis of a CJC with DAC and ipamorelin blend for identity confirmation and separate quantification of both peptides in mg per vial.

This analysis is designed to confirm the identity and separately determine the amount of CJC with DAC and ipamorelin in a combined lyophilized sample. HPLC testing measures the content of both target peptides, with results reported in mg per vial.Peptide purity cannot be reliably determined in a blend because impurities originating from the individual peptides may overlap in the chromatographic data and cannot be clearly attributed to a specific component.<h4>CJC with DAC and Ipamorelin</h4>CJC-1295 with DAC is a synthetic long-acting analogue of growth hormone-releasing hormone (GHRH). The Drug Affinity Complex modification extends its presence in circulation by enabling binding to albumin.Ipamorelin is a synthetic peptide classified as a selective growth hormone secretagogue. It acts as an agonist of the growth hormone secretagogue receptor, also known as the ghrelin receptor.This analysis is intended for samples containing both peptides in a single blend. The final report provides the identity and amount of each target compound separately.<h4>What the Analysis Determines</h4><ul><li>Identity of CJC with DAC</li><li>Identity of ipamorelin</li><li>Amount of CJC with DAC in the sample</li><li>Amount of ipamorelin in the sample</li><li>Results in mg per vial for each target peptide</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: CJC with DAC and ipamorelin</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format: mg per vial for each target peptide</li><li>Minimum sample amount: one whole unopened vial containing the lyophilizate</li><li>Average turnaround time: 7 business days</li><li>Peptide purity: not measured</li></ul><blockquote><h5>Important Notice</h5>Peptide purity cannot be determined for a CJC with DAC and ipamorelin blend. Impurities associated with both peptides may overlap in the chromatographic data and cannot be reliably assigned to the individual target compounds.The final report provides identification and separately measured amounts of CJC with DAC and ipamorelin. Peptide purity is not included in the results.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

CJC No DAC – MOD GRF (1-29)/Ipamorelin Blend Analysis

HPLC analysis of a CJC No DAC – MOD GRF (1-29) and ipamorelin blend for identification and separate quantification of both peptides in mg per vial.

This analysis is designed to confirm the identity and separately determine the amount of CJC No DAC – MOD GRF (1-29) and ipamorelin in a combined lyophilized sample. HPLC testing measures both target peptides, with results reported in mg per vial.Peptide purity cannot be reliably determined in blends because impurities originating from the individual peptides may overlap in the chromatographic data and cannot be clearly attributed to a specific component.<h4>CJC No DAC – MOD GRF (1-29) and Ipamorelin</h4>CJC No DAC, also known as MOD GRF (1-29), and ipamorelin are two separate peptides that may be combined in a single product. This analysis is specifically intended for blends containing both target compounds.The final report confirms the identity of both peptides and states the amounts of CJC No DAC – MOD GRF (1-29) and ipamorelin separately.<h4>What the Analysis Determines</h4><ul><li>Identity of CJC No DAC – MOD GRF (1-29)</li><li>Identity of ipamorelin</li><li>Amount of CJC No DAC – MOD GRF (1-29) in the sample</li><li>Amount of ipamorelin in the sample</li><li>Results in mg per vial for each target peptide</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: CJC No DAC – MOD GRF (1-29) and ipamorelin</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format: mg per vial for each target peptide</li><li>Minimum sample amount: one whole unopened vial containing the lyophilizate</li><li>Average turnaround time: 7 business days</li><li>Peptide purity: not measured</li></ul><blockquote><h5>Important Notice</h5>Peptide purity cannot be determined for a CJC No DAC – MOD GRF (1-29) and ipamorelin blend. Impurities associated with both peptides may overlap in the chromatographic data and cannot be reliably assigned to the individual target compounds.The final report provides identification and separately measured amounts of both peptides. Peptide purity is not included in the results.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Products from category Laboratory analyses - page 10

Related content

ISC 2026 - Day 2

Basic Principles of Gas Chromatography - Separation and Analysis

CEITEC Scientists Are the First to Capture How Enteroviruses Initiate Infection